Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment of Newly Diagnosed Glioblastoma with Concomitant and Adjuvant Temozolomide and Radiotherapy

Treatment of Newly Diagnosed Glioblastoma with Concomitant and Adjuvant Temozolomide and... Background and aim:In the UK, the current management of high-grade gliomas consists of maximal surgical debulking, where possible, followed by radiotherapy. A large, randomized, multicenter trial assessing the addition of temozolomide to radiotherapy found a significant increase in median survival of the order of 2.5 months in favor of the combined treatment (14.6 vs 12.1 months; p < 0.001). Our center has considerable experience with temozolomide and has treated patients with a regimen similar to that used in the above trial. The aim of this study was to confirm whether these results are translated into a benefit when used in clinical practice in the UK. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Treatment of Newly Diagnosed Glioblastoma with Concomitant and Adjuvant Temozolomide and Radiotherapy

Loading next page...
 
/lp/springer-journals/treatment-of-newly-diagnosed-glioblastoma-with-concomitant-and-P3zV8DjtA9
Publisher
Springer Journals
Copyright
Copyright © 2006 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200605060-00008
Publisher site
See Article on Publisher Site

Abstract

Background and aim:In the UK, the current management of high-grade gliomas consists of maximal surgical debulking, where possible, followed by radiotherapy. A large, randomized, multicenter trial assessing the addition of temozolomide to radiotherapy found a significant increase in median survival of the order of 2.5 months in favor of the combined treatment (14.6 vs 12.1 months; p < 0.001). Our center has considerable experience with temozolomide and has treated patients with a regimen similar to that used in the above trial. The aim of this study was to confirm whether these results are translated into a benefit when used in clinical practice in the UK.

Journal

American Journal of CancerSpringer Journals

Published: Aug 9, 2012

References